Century Therapeutics, Inc. (IPSC) — SEC Financial Statements & Analysis

Century Therapeutics, Inc. (IPSC) is a biological products, (no diagnostic substances) company, incorporated in DE. Century Therapeutics, Inc. trades on Nasdaq as: IPSC. Century Therapeutics, Inc. (IPSC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Century Therapeutics, Inc. carries a market cap of $504.16M, a P/E ratio of -4.59x, a P/B ratio of 2.17x, a P/S ratio of 4.62x, an enterprise value of $452.16M, and an EV/EBITDA multiple of -4.21x. On profitability, it posts an operating margin of -107.17%, a net margin of -100.58%, a Return on Equity (ROE) of -49.65%, a Return on Assets (ROA) of -38.41%, and a Return on Invested Capital (ROIC) of -69.81%. Per share, it reports EPS of $-0.53, diluted EPS of $-0.53, free cash flow per share of $-0.43, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -5.69% year-over-year, net income growth of 371.66% year-over-year, and EPS growth of 97.67% year-over-year. On the balance sheet, it maintains a current ratio of 8.28x, a quick ratio of 7.94x, working capital of $109.70M, a debt-to-equity ratio of 0.24x, a debt ratio of 0.19, an interest coverage ratio of -267.81x, free cash flow of $-88.37M (TTM), and net debt of $-52.00M. Figures sourced from SEC EDGAR.

Market Cap

$504.16M

P/E TTM

-4.59x

EPS TTM

$-0.53

P/B TTM

2.17x

ROE TTM

-49.65%

ROA TTM

-38.41%

Debt To Equity

0.24x

Free Cash Flow TTM

$-88.37M

Net Revenue TTM Growth 1Y

-5.69%

Data as of 2026-06-30 · Source: SEC EDGAR